Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias

• Published in: Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-10, Vol.17 (10), p.684-695.e6
• Main Authors: Cortes, Jorge E., MD, Gambacorti-Passerini, Carlo, MD, Kim, Dong-Wook, MD, PhD, Kantarjian, Hagop M., MD, Lipton, Jeff H., MD, PhD, FRCPC, Lahoti, Amit, MD, Talpaz, Moshe, MD, Matczak, Ewa, MD, Barry, Elly, MD, Leip, Eric, PhD, Brümmendorf, Tim H., MD, Khoury, H. Jean, MD, FACP
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adverse events; Aged; Aged, 80 and over; Aniline Compounds - administration & dosage; Aniline Compounds - adverse effects; Aniline Compounds - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chronic myeloid leukemia; Clinical Trials as Topic; Creatinine - blood; Female; Glomerular Filtration Rate - drug effects; Hematology, Oncology and Palliative Medicine; Humans; Kidney Diseases - diagnosis; Kidney Diseases - etiology; Kidney Function Tests; Leukemia - complications; Leukemia - diagnosis; Leukemia - drug therapy; Leukemia - genetics; Male; Middle Aged; Neoplasm Staging; Nitriles - administration & dosage; Nitriles - adverse effects; Nitriles - therapeutic use; Patient Outcome Assessment; Philadelphia Chromosome; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Quinolines - administration & dosage; Quinolines - adverse effects; Quinolines - therapeutic use; Renal toxicity; Retrospective Studies; Tyrosine kinase inhibitors; Young Adult
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2017.06.001

Abstract Purpose To assess renal function in patients with Philadelphia chromosome-positive leukemias receiving bosutinib or imatinib. Patients and Methods Patients received first-line bosutinib (n=248) or imatinib (n=251; phase 3 trial), or second-line or later bosutinib (phase 1/2 trial; N=570).Adverse events (AEs) and changes from baseline in estimated glomerular filtration rate (eGFR) and serum creatinine were assessed. Results Time from last patient’s first dose to data cutoff was ≥48 months. Renal AEs were reported in 13% of patients receiving second-line or later bosutinib, and in 9% and 6% receiving first-line bosutinib and imatinib, respectively. eGFR in patients receiving bosutinib declined over time with more patients developing grade ≥3b eGFR (